Kornimate/medical-research-clean huggingface dataset:
effect of zumba dance on premenstrual tension

Conditions: Premenstrual Tension

Summary: each female sets her experience of 47 manifestations on a 6 point scale separately for the premenstrual, menstrual and intermenstrual phases of her latest and worst menstrual cycle. daily symptoms report will be filled at the start and at end of the study (before and after performing swimming exercise) females in group i will be instructed to engage into 12 classes of 60-minute zumba® fitness over an 8-week period.

each female sets her experience of 47 manifestations on a 6 point scale separately for the premenstrual, menstrual and intermenstrual phases of her latest and worst menstrual cycle. daily symptoms report will be filled at the start and at end of the study (before and after performing swimming exercise) females in group i will be instructed to engage into 12 classes of 60-minute zumba® fitness over an 8-week period each class was one hour in length and a recovery period of at least 48 hours will be taken between classes. the zumba® fitness scheduling of sessions will be self-selected by the participants. the zumba sessions will be conducted at a ﬁtness center (samia allouba gym and fitness center) and will consist of continuous dance movements to latin music with varying intensity level throughout the sessions. each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. at the end of the training session, the intensity will be gradually reduced. the zumba sessions will be supervised by three certiﬁed zumba instructors, each responsible for regular sessions per week.

Eligibility criteria:
inclusion criteria: 1. age:18-25 years. 2. bmi :18-25 kg/m2. 3. a regular menstrual cycle of 23-35 days duration. 4. no previous practice of zumba. 5. free from musculoskeletal injury. 6. all women did not use oral contraceptive pills or any psychotropic agents. exclusion criteria: 1. pregnancy. 2. metabolic/cardiorespiratory contraindications to physical exercise. 3. cigarette smokers. 4. recovering from a major injury or illness; or using anti-inflammatory, hyperlipidemia or hypertension medication. 5. any abnormality in ovulation or those with pelvic inflammatory diseases (pid) or a history of endometriosis. 6. women with endocrine abnormality as diabetes mellitus, thyroid, pituitary, or ovarian disorders. 7. women who are taking any hormonal drugs or drugs that affect hormones as antidepressant drugs during the preceding three months before the study.
responsiveness and minimal clinically important difference (mcid) of knee injury and osteoarthritis (koos-12) in (oa)

Conditions: Knee Osteoarthritis

Summary: osteoarthritis (oa) is a common and disabling constant musculoskeletal disorder that causes significant weight on individual, health care systems, and social economy. with the maturing of the populace and the commonness of undesirable way of life practices, the predominance and disease burden of oa are expanding day by day. different non-surgical interventions have been introduced worldwide for the treatment of knee oa. the aim of this study is to determine the responsiveness and minimal clinically important difference for knee injury and osteoarthritis outcome score-12 in knee oa patients respectively.


Eligibility criteria:
inclusion criteria: * an age group of 50-65 years will be included in study. * both males and females will be included. * patients with unilateral knee oa with k-l grade ii-iii involving medial side will be a part of study. * following acr (american college of rheumatology) guidelines patient with knee pain must have 3 or more than 3 of the following symptoms i.e. age \>50 years, morning stiffness \<30 minutes, crepitus on movement, tenderness, bony enlargements, no palpable warmth will also be a part of study. * patient having pain ranging from 5-8 on numeral pain rating scale (nprs) will be included exclusion criteria: * participants with traumatic knee injuries (cruciate injuries, meniscal injuries etc.) will be excluded. * osteonecrosis patients will be excluded. * patient with neurological problems won't be a part of this study. * people having metastasis or neoplasm will be omitted. * knee or hip fractures * rheumatoid arthritis, systemic lupus erythematosus (sle) or other autoimmune disease people will be listed out.
tranilast plus allopurinol in patients with moderate to severe gout (tango)

Conditions: Moderate to Severe Gout; Hyperuricemia

Summary: this phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe gout.


Eligibility criteria:
inclusion criteria: * male or female, aged 18 to 80 * severe gout, demonstrated by 3 or more gout flares in the previous 12 months, or the presence of at least one gout tophus or gouty arthritis * hyperuricemia with a sua ≥8.0 mg/dl exclusion criteria: * pregnant or nursing * known hypersensitivity to any of the components of tranilast or allopurinol * known history of xanthinuria or kidney stones * use of an investigational drug within 30 days * presence of, or history of, cancer with the exception of completely excised, non-metastatic squamous cell and basal cell carcinomas of the skin * subject is planning or likely to require a surgical procedure during the study

Keywords: moderate to severe gout hyperuricemia
antiplatelet therapy for ais patients with thrombocytopenia

Conditions: Acute Ischemic Stroke; Thrombocytopenia

Summary: the goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (ais) patients with thrombocytopenia. participants will be prescribed antiplatelet agents and followed up for 3 months.

antiplatelet therapy is widely used in non-cardiogenic ais patients for secondary prevention. however, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. the goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (ais) patients with thrombocytopenia. participants will be prescribed antiplatelet agents and followed up for 3 months.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * acute ischemic stroke or transient ischemic attack with onset \< 7 days * the last blood routine test before enrollment indicates platelet count \ 30 x 10\^9 exclusion criteria: * chronic renal dysfunction (gfr \< 30ml/min) or severe hepatic injury * indications for anticoagulation therapy, e.g. atrial fibrillation * myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past * have or plan to receive cea or cas in the following 3 months * life expectancy less than 1 year * plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding * pregnant or lactating women * individuals identified by researchers as unsuitable for participation in the study due to other reasons.
neutrophils in bone sarcomas

Conditions: Osteosarcoma, Chondrosarcoma

Summary: hypothesis: tumor infiltrating neutrophils are present in osteosarcomas and chondrosarcomas and experimental design: exploratory observational research population: adult patients with osteosarcoma or chondrosarcoma assessment criteria: determination of the presence of tans within tumors and their n1 or n2 profile, the presence of other immune cells, and the pdl-1 status of the tumor. investigation plan: proposal to participate at all eligible patient during the preoperative consultation. if the patient agrees to participate in the study he/she will be included. participation in the study will not affect its coverage. patient participation will lead to: * taking samples from an operative part, * the collection of demographic data (age, sex, height, weight, body mass index), family history of cancer, history of bone trauma, sports practice, clinical and anatomopathology reports and data, medical history (diabetes, cardiovascular diseases, infectious diseases, autoimmune diseases, bone metabolism disorders, allergies, menopause, drug treatments followed, psychiatric disorders). statistical analysis plan: description in frequency of the presence of tans, of n1 and n2 profiles, of the presence of other immune cells both qualitatively and quantitatively. analysis in subgroups on relevant criteria (age, sex, location, type of tumor).


Eligibility criteria:
inclusion criteria: * patient of 18 years and more * patient of the orthopedic and traumatological surgery department of the reims university hospital or the godinot institute * patient with osteosarcoma or chondrosarcoma to be operated on regardless of stage. * patient agreeing to participate in the study (informed consent form) * patient fluent in french * patient affiliated with a social security regimen exclusion criteria: * patient having a medical history that may compromise the protocol (psychiatric, medical or pharmacological disorders such as the use of anti-inflammatory drugs, or any compound that may alter or modify the inflammatory reaction in the week preceding the protocol). * pregnant or breastfeeding women * patient with eating disorders (anorexia, bulimia, overeating) * patient protected by law (guardianship, curatorship, hospitalized without their consent and not protected by law, deprived of liberty)

Keywords: osteosarcoma chondrosarcoma tumor associated neutrophils
genome studies of hepatocellular carcinoma developed in hepatitis c patients with sustained virological response

Conditions: Hepatocellular Carcinoma; Hepatitis C

Summary: in this international collaboration study, the research group will analyze somatic mutations of hepatocellular carcinoma (hcc) developed after sustained virological response (svr) in patients treated with hepatitis c (hcv) therapy

method paired liver tissue samples will be collected from the tumour sections and also from the adjacent non-tumour tissues, for comparison in each individual. the tissues have been collected as part of routine clinical work/other studies, by liver biopsies or at liver resection/liver transplantation. data regarding the patient characteristic will be collected. whole genome sequencing analyses are planned to be performed.

Eligibility criteria:
inclusion criteria: * patients with sustained virological response (svr) after interferon (ifn)-containing or ifn-free treatment, and developed hepatocellular carcinoma (hcc) * available liver biopsies from hepatocellular carcinoma and non-hcc tissue exclusion criteria: * co-infection with chronic hepatitis b (hbsag positive) or hiv infection. * liver transplantation prior to treatment-start, leading to svr. * patients with diagnosed hcc prior to treatment-start, leading to svr.

Keywords: sustained virological response whole genome sequencing
superior trunk block catheter versus single-shot superior trunk block with intravenous dexmedetomidine for shoulder arthroplasty

Conditions: Shoulder Arthroplasty; Postoperative Pain

Summary: shoulder arthroplasty is associated with significant postoperative pain. appropriate pain control after shoulder arthroplasty is crucial for postoperative rehabilitation and patient satisfaction. superior trunk block is a commonly employed regional anesthetic technique for shouler arthroplasty, and a continuous catheter is often placed to extend the analgesic benefit of the block. however, continuous peripheral nervel block (pnb) is more costly and time-consuming than sigle-shot pnb. recent evidence suggests that intravenous (iv) dexmedetomidine (dex) prolong the analgesic duration after sigle-shot pnb. the investigators will compare continuous superior trunk block with single-shot superior trunk block with iv dex in patients undergoing shoulder arthroplasty.


Eligibility criteria:
inclusion criteria: 1 patients aged 19 years old or older, with american society of anesthesiologists physical status 1-3, and scheduled for elective shoulder arthroplasty exclusion criteria: 1. allergy or intolerance to any of the drugs used in the study 2. heart failure 3. hepatic or renal insufficiency 4. opioid dependency 5. coagulopathy 6. pre-existing neurologic or anatomic deficits in the upper extremities 7. severe psychiatric illness
quantification and description of the increase in serum troponin following acute coronary syndrome

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Unstable Angina

Summary: the new assay of troponins t (highly sensitive troponins) detects concentrations much lower than before. few data are currently available on their kinetics during acute coronary syndrome, especially in regard to the correlation with ck mb. the aim of the present study is to describe the kinetic of highly sensitive troponins in acute coronary syndrome, to correlate it with the concentration of ck mb, and possibly to evaluate their prognostic value with respect to infarct size .

patients who meet the inclusion criteria will have a highly sensitive troponins and ckmb assays q 8hr for the first day, and q 12h for the next 2 days. if clinically not indicated, the blood sample can be cancelled at any time, as in the case of a patient with an initial suspicion of acute coronary syndrome in which the final diagnosis is something else. only patients with a definitive myocardial infarction will be analyzed. subgroup analyses includes st-elevation mi, non st-elevation mi, revascularization vs no revascularization, procedural myocardial infarction. another analysis conducted is the correlation between the values of troponin and infarct size by echocardiography (in patients who have an echocardiography 2-7 days post and 2-6 months post myocardial infarction)

Eligibility criteria:
inclusion criteria: * \>= 18 years-old * clinical suspicion of an acute coronary syndrome; (will be analyzed only patients with aposteriori definitive diagnosis of unstable angina or myocardial infarction) exclusion criteria: * none

Keywords: creatine kinase, mb form troponin acute coronary syndrome myocardial infarction unstable angina
effectiveness of early intervention in transfusion independent aplastic anemia: a retrospective medical claims database study

Conditions: Aplastic Anemia (AA)

Summary: this was a retrospective non-interventional cohort study with secondary use of data from the medical data vision (mdv) hospital-based database to evaluate the effectiveness of early drug intervention in preventing transfusion compared to watchful observation among adult transfusion-independent aplastic anemia (aa) patients in japan.


Eligibility criteria:
inclusion criteria: * having at least one confirmed diagnosis of aa within the selection period (1 inpatient or 2 outpatient claims per the international statistical classification of diseases, 10th revision \[icd-10\] code, without any suspicion flag). * being aged 15 to 90 years at the index date. * having at least 3 months of continuous enrolment prior to the index date. exclusion criteria: * having a blood transfusion recorded any time before the index date. * having anti-thymocyte globulin (atg) treatment recorded within 3 months after the index date. * having at least one prescription record for any of the drug treatments of interest any time before the index date. * having a diagnosis of acute myeloid leukemia (aml), chronic myelomonocytic leukemia (cmml) or other leukemia any time before the index date. * having an aa diagnosis (without suspicious flag) date earlier than the start of patient's observation in the database. * having less than 6 months of continuous follow-up. safety population - additional exclusion criterion: - having a diagnosis of hepatotoxicity, kidney dysfunction, hypertension, or diabetes mellitus any time before the index date.
treatment of unfavorable bleeding patterns in contraceptive implant users

Conditions: Bleeding; Implants; Breakthrough Bleeding

Summary: the etonogestrel (eng) subdermal contraceptive implant (eng implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women. the only study to demonstrate a sustained reduction in bleeding lasting for two months was the selective estrogen receptor modulator (serm) tamoxifen in users of the levonogestrel (lng) contraceptive implant. based on the investigators encouraging preliminary data of tamoxifen and eng implant users, the investigators plan to perform additional studies on the impact of tamoxifen on the breakthrough bleeding experience by eng implant users.

the investigators will perform a 2 phase trial for treatment of women experiencing frequent or prolonged bleeding while using the eng contraceptive implant. the first phase will consist of a randomized, controlled, double blind placebo-controlled clinical trial over a 90-day reference period and the second phase will allow both study arms to receive open-label treatment over an additional 90-day reference period. the primary outcome of the study will be the total number of consecutive bleeding-free days in first 30 days from day 1 of first treatment (tx1).

Eligibility criteria:
inclusion criteria: * english or spanish speaking * women aged 15-45 years of age * currently using the eng-implant for at least 1 month and use proven on exam (palpation of implant at screening visit) * willing to continue using the implant for at least 6 months * \>7 days of continuous bleeding/spotting, or 2 or more episodes of bleeding/spotting in the last 30 days. * cellphone that is able to receive and respond to a daily text or email message . exclusion criteria: * postpartum within six months * post-abortion within six weeks * currently pregnant * currently breast-feeding * undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant * bleeding dyscrasia * anticoagulation use * active cervicitis * allergy to tamoxifen * history of venous thromboembolism * current or past breast or uterine malignancy * use of medication contraindicated with tamoxifen (coumadin, letrozole, bromocriptine, rifampicin, aminoglutethimide, phenobarbital).

Keywords: unscheduled bleeding long acting contraception
effect of magnesium sulphate added to mepivacaine hydrochloride on inferior alveolar nerve block success in patients with symptomatic irreversible pulpitis in mandibular molars: a randomized clinical trial.

Conditions: Success of Inferior Alveolar Nerve Block

Summary: the study is conducted to assess the effect of adding magnesium sulphate to mepivacaine hcl compared to mepivacaine hcl alone on the success of inferior alveolar nerve block in patients with symptomatic irreversible pulpitis in mandibular molars


Eligibility criteria:
inclusion criteria: 1. age between 18-55 years old. 2. systemically healthy patient (asa i or ii). 3. mandibular molar teeth with: * preoperative sharp pain. * no widening in the periodontal ligament (pdl). * vital response of pulp tissue to cold pulp tester (ethyl chloride spray)1. * fully formed roots. 4. positive patient's acceptance for participation in the study. exclusion criteria: 1. patients who had used any type of analgesic medication during the preceding 12 hours before the treatment. 2. pregnant or nursing females. 3. patients having significant systemic disorder (asa iii or iv). 4. drug abusers and subjects who were on antidepressant medication. 5. re-treatment cases. 6. patients with a contraindication for the use of magnesium sulphate or those known to be allergic to any of the study medications.
the movi-hiit pilot trial: the impact of activity breaks on cognitive function, adiposity and fitness in preschoolers

Conditions: Physical Activity; Obesity, Childhood; Cardiovascular Diseases; High Intensity Interval Training; Cognition

Summary: pilot study to test the acceptability and feasibility of an intervention aimed to test the effectiveness, in preschool children, of an integrated physical activity intervention in the classroom based on intervallic training (movi-hiit) on improving executive function, body composition and cardiorespiratory fitness.

the evolution of the movi studies, conducted by the research group, has led to create the last project (movi-hiit; clinicaltrials.gov identifier: nct04863040). this pilot study will include children aged 4-6 years from 2 public schools of the province of ciudad real, spain, with 2 arms (intervention and control) and the intervention will last 8 weeks. the intervention proposed in the study is implemented through an online platform developed to achieved the intensities required for the age-range of participants, but this platform has never been tested accurately in the classroom. thus, it seems necessary to pilot the intervention to evaluate the acceptability and feasibility of the intervention, in order to improve facts, if necessary, to achieved proposed objectives.

Eligibility criteria:
inclusion criteria: * the participating schoolchildren must belong to the 2nd and 3rd year of preschool education, not have any malformation that prevents them from learning the spanish language (or spanish sign language), not have any type of physical or mental disorder that parents and/or teachers have identified that prevents the performance of physical activities, not suffer from any chronic disease such as heart disease, diabetes or asthma that, according to the criteria of their pediatrician - after analysis of the program of activities - prevents their participation in the measurements and/or the intervention. * as this is an intervention in the classroom, the school faculty will include the active breaks proposed in the center's programming, for which reason the intervention will be received by all the children in the intervention group school. however, the investigators will consider school participants to be those who have the consent of the parent or guardian for participation in the study. in addition, schoolchildren must verbally express their willingness to participate in the baseline and final physical examinations. exclusion criteria: * children with severe spanish language learning difficulties. * children with serious physical or mental disorders identified by parents or teachers that would impede participation in the programme's activities. * children diagnoses of chronic disorders, such as heart disease, diabetes or asthma, which in the opinion of their paediatricians would prevent their participation in the programme's activities (movi-hiit)

Keywords: children obesity high intensity interval training cognition cardiorespiratory fitness aerobic capacity preschool adiposity physical activity
breathing exercises on depression in postmenopausal women

Conditions: Postmenopausal; Depressive Symptom; Breathing Exercises

Summary: evaluate the effect of breathing exercises on depression and sexual function in postmenopausal women

sixty postmenopausal women will be sourced from the obstetrics \& gynecology outpatient clinic at el mahalla el kobra general hospital in egypt, with referrals from gynecologists. patients will be randomly assigned into two groups. study group: it will include 30 women participating in diaphragmatic breathing plus aerobic training. control group: it will include 30 women participating in aerobic training. at baseline and poststudy, the following outcomes will be assessed: 1. depression (beck depression inventory ii scale). 2. sexual function (female sexual function index questionnaire).

Eligibility criteria:
inclusion criteria: * minimum of 3 years after menopause. * mild to moderate depression. * mild to moderate sexual dysfunction. * their ages will be ranged from 45 to 60 years old. * their bmi will be less than 30 kg/m2. exclusion criteria: * prolapse of the pelvic organs. * pelvic tumors. * vaginal infections. * musculoskeletal/ neurological limitations to exercise. * psychiatric disorders. * unstable cardiovascular conditions. * diabetes.